Pharming Group N.V. (PHAR)
Nasdaq · Healthcare · Biotechnology
$9.80+0.51%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $694M
- P/E (trailing)
- 75.4
- Forward P/E
- 31.9
- 52-week range
- $9.62 – $21.34
- 52-week change
- −33.54%
- EPS (trailing)
- $0.13
- Analyst rating
- 1.0 Strong buy
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Headquarters: Leiden, Netherlands · 407 employees · pharming.com